AR006202A1 - Usos de antagonista ige para preparar un medicamento util para el tratamiento de las enfermedades alergicas y composiciones que los contiene - Google Patents

Usos de antagonista ige para preparar un medicamento util para el tratamiento de las enfermedades alergicas y composiciones que los contiene

Info

Publication number
AR006202A1
AR006202A1 ARP970100986A ARP970100986A AR006202A1 AR 006202 A1 AR006202 A1 AR 006202A1 AR P970100986 A ARP970100986 A AR P970100986A AR P970100986 A ARP970100986 A AR P970100986A AR 006202 A1 AR006202 A1 AR 006202A1
Authority
AR
Argentina
Prior art keywords
prepare
treatment
ige
ige antagonist
compositions containing
Prior art date
Application number
ARP970100986A
Other languages
English (en)
Original Assignee
Univ Johns Hopkins
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins, Genentech Inc filed Critical Univ Johns Hopkins
Publication of AR006202A1 publication Critical patent/AR006202A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Usos y composiciones de antagonista IgE para preparar un medicamento útil para el tratamiento de una enfermedad alérgica caracterizado por una cantidadefectiva de dicho antagonista IgE, que es administrado como: (a) una dosis de carga durante unperíodo de al menos alrededor de 14 días suficientes parareducir el nivel promedio de IgE libre en suero del paciente hasta un nivel no mayor de alrededor de 50ng/ml al final del período de carga; seguido por (b)una dosis de mantenimiento entrealre dedor de 8x10(5) hasta 2.4x10(3) mg/kg/semana del antagonista IgE para cada IU/ml línea de base IgE libre en elsuero del paciente.
ARP970100986A 1996-03-12 1997-03-12 Usos de antagonista ige para preparar un medicamento util para el tratamiento de las enfermedades alergicas y composiciones que los contiene AR006202A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61422096A 1996-03-12 1996-03-12

Publications (1)

Publication Number Publication Date
AR006202A1 true AR006202A1 (es) 1999-08-11

Family

ID=24460327

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970100986A AR006202A1 (es) 1996-03-12 1997-03-12 Usos de antagonista ige para preparar un medicamento util para el tratamiento de las enfermedades alergicas y composiciones que los contiene

Country Status (8)

Country Link
EP (1) EP0904108A1 (es)
JP (1) JP2001505181A (es)
AR (1) AR006202A1 (es)
AU (1) AU726143B2 (es)
CA (1) CA2246427A1 (es)
IL (1) IL126113A0 (es)
WO (1) WO1997033616A1 (es)
ZA (1) ZA971607B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US7393529B2 (en) 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
AU2065801A (en) * 1999-12-06 2001-06-12 Panacea Pharmaceuticals, Llc Passive desensitization
GB0016441D0 (en) 2000-07-04 2000-08-23 Pharmagene Lab Limited Therapeutic method
US6787524B2 (en) 2000-09-22 2004-09-07 Tanox, Inc. CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies
US20040146502A1 (en) * 2001-05-03 2004-07-29 Elisabeth Latour Use of organic compounds
GB201610198D0 (en) * 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
CN114028569B (zh) * 2021-12-20 2023-04-28 中国医学科学院基础医学研究所 免疫球蛋白IgE在诊断和/或治疗高血压中的用途
CN114504644B (zh) * 2021-12-24 2024-02-13 北京大学第一医院 抗IgE抗体在用于治疗腺样体肥大中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5449760A (en) * 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US4940715A (en) * 1988-05-17 1990-07-10 Kissei Pharmaceutical Co., Ltd. 5H-pyrazolo[4,3-A] quinolizin-5-one compounds exhibiting therapeutic activities
JP3156237B2 (ja) * 1991-12-24 2001-04-16 雪印乳業株式会社 抗ヒトＩｇＥ モノクローナル抗体

Also Published As

Publication number Publication date
WO1997033616A1 (en) 1997-09-18
IL126113A0 (en) 1999-05-09
AU1987597A (en) 1997-10-01
JP2001505181A (ja) 2001-04-17
AU726143B2 (en) 2000-11-02
CA2246427A1 (en) 1997-09-18
EP0904108A1 (en) 1999-03-31
ZA971607B (en) 1998-08-25

Similar Documents

Publication Publication Date Title
DK0490944T3 (da) Transmucosal doseringsform
ES2171469T3 (es) Composicion administrada por via nasal y preparacion que la contiene.
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
PT88985A (pt) Processo para a preparacao de composicoes farmaceuticas nasais e ou oftalmicas contendo azelastina
EP1064000A4 (en) VITAMIN D AND ITS ANALOGS FOR THE TREATMENT OF TUMORS AND OTHER HYPERPROLIFERATION DISORDERS
DE69230112D1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
ES2182899T3 (es) Formulacion farmaceutica para la administracion subcutanea, intramuscular o intradermica de factor viii.
ATE94393T1 (de) Dosisform zur oralen verabreichung des hypoglykaemischen glipizids.
ATE92762T1 (de) Medikamente.
MX173567B (es) Procedimiento para preparar una composicion farmaceutica y composicion farmaceutica para mejorar los sintomas de enfermedad inducida por vih o reducir la transcripcion y proliferacion del vih
AU1935788A (en) A process for producing an administration and/or dosage form for medically active ingredients of drugs
ES2139842T3 (es) Uso de la melatonina para tratar a pacientes que sufren drogodependencia.
DK0412554T3 (da) Sustained-release-præparat til administration i hjernen
ES2119748T3 (es) Composicion farmaceutica que contiene un farmaco ligeramente soluble en agua.
KR890006227A (ko) 페놀-함유 진해성 액체 조성물
ES2115571T3 (es) Uso de polisulfato de pentosana para la resolucion de cicatrices en enfermedades vasculares progresivas cronicas.
JPH01261334A (ja) アンギオテンシン転換酵素阻害剤を有効成分とした医療用調剤及びその製造方法
JPS6360940A (ja) 白内障の予防または治療剤
ES2038847T3 (es) Proceso para la preparacion de una composicion farmacutica conteniendo zidovudine e inosiplex para el tratamiento del sida y sindromes afines.
ES2211594T3 (es) Medicamentos que contienen acido pantotenico para el tratamiento de enfermedades inflamatorias de las articulaciones.
AR034036A1 (es) Inhibidor de aromatasa en una dosis unica para tratar la infertilidad
EP0402208B1 (fr) Association de vitamine A à dose physiologique et de différents principes actifs ayant une activité thérapeutique
ATE259223T1 (de) Pharmazeutische zusammensetzung die einen no donor enthält und dessen therapeutische anwendung
Ayres Hailey-Hailey disease: response to vitamin E therapy
AR062894A1 (es) Formulaciones para administracion terapeutica de hormona de estimulacion del tiroides (ths)